Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Bronchiectasis
Interventions
DRUG

Ciprofloxacin (Cipro, BAYQ3939)

Inhalation of 32,5mg Ciprofloxacin inhaled twice a day

DRUG

Placebo

Inhalation of matching placebo twice a day

Trial Locations (47)

2139

Concord

3084

Heidelberg

3181

Prahran

4101

South Brisbane

4102

Woollongabba

5000

Adelaide

5065

Adelaide

6009

Nedlands

10961

Berlin

11501

Mineola

12203

Berlin

13507

Berlin

14059

Berlin

15562

Rüdersdorf

15706

Santiago de Compostela

21502

Geesthacht

22927

Großhansdorf

30167

Hanover

30625

Hanover

46360

Michigan City

55131

Mainz

56068

Koblenz

58452

Witten

60596

Frankfurt am Main

63571

Gelnhausen

72205

Little Rock

74245

Löwenstein

77204

Houston

80206

Denver

84651

Payson

92037

La Jolla

99437

Bad Berka

06030

Farmington

20007-2197

Washington D.C.

34109-0446

Naples

75708-3154

Tyler

06080

Badajoz

08036

Barcelona

07010

Palma de Mallorca

751 85

Uppsala

BS2 8HW

Bristol

CB3 8RE

Cambridge

L9 7JU

Liverpool

BT12 7AB

Belfast

NE7 7DN

Newcastle upon Tyne

EH16 4SA

Edinburgh

NR4 7UY

Norwich

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Bayer

INDUSTRY

NCT00930982 - Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis | Biotech Hunter | Biotech Hunter